400 SPECTRUM CENTER DRIVE, IRVINE, CA
Reports 2025 Year End Financial Results and Provides Business Updates
CG Oncology, Inc. Files Amendment No. 1 for $550 Million Common Stock Offering
Investor Presentation
Appointment of Christina Rossi to CG Oncology Board of Directors
Reports Third Quarter 2025 Financial Results and Provides Business Updates
Resignation of Robert Lapetina as Principal Financial Officer
Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months
FY 2024
Q2
Q1
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
S-1
Amended Registration Statement for Securities
Definitive Proxy Statement
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Initial Statement of Beneficial Ownership